Cholesterol is the only lipid whose absorption in the gastrointestinal tract is limited by gate‐
keeping transporters and efflux mechanisms, preventing its rapid absorption and …

Non-alcoholic fatty liver disease (NAFLD) parallels comorbidities such as metabolic
syndrome, dyslipidaemia or diabetes. Although NAFLD is very prevalent in overweight …

The purpose of this study is to establish and validate an accurate and personalized
nonalcoholic fatty liver disease (NAFLD) prediction model based on the nonobese …

To date, there are few studies that have evaluated the prognostic impact of changes in
abdominal obesity or weight on long-term adverse kidney outcomes in non-alcoholic fatty …

Objective Previous research conducted in Russia showed that the number of patients with
non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidities is large …

Polymorphisms of group VIA calcium-independent phospholipase A2 (iPLA2β or PLA2G6)
are positively associated with adiposity, blood lipids, and Type-2 diabetes. The ubiquitously …

Methods Data from the National Health Insurance Corporation 2009 to 2012 were analyzed.
NAFLD disease was defined as a fatty liver index> 60 in the absence of alcohol …

Obesity and its associated non-alcoholic fatty liver disease (NAFLD) have become epidemic
medical problems worldwide; however, the current available therapeutic options are limited …

Nonalcoholic fatty liver disease (NAFLD) is characterized by a spectrum of diseases,
ranging from simple steatosis to hepatocellular carcinoma. The main factors for NAFLD are …

Objective Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and insulin
resistance; however, there is a group of non-obese patients with NAFLD that need to be …